

MarÃ-a Isabel Lucena GonzÃ¡lez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2196569/publications.pdf>

Version: 2024-02-01

164
papers

9,386
citations

50566

48
h-index

46524

93
g-index

176
all docs

176
docs citations

176
times ranked

6571
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.	0.6	847
2	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.	0.6	595
3	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347.	0.6	412
4	Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019, 5, 58.	18.1	409
5	Drug-induced liver injury: Interactions between drug properties and host factors. <i>Journal of Hepatology</i> , 2015, 63, 503-514.	1.8	319
6	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. <i>Hepatology</i> , 2011, 54, 931-939.	3.6	279
7	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006, 44, 1581-1588.	3.6	267
8	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. <i>Hepatology</i> , 2009, 49, 2001-2009.	3.6	266
9	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5.	0.6	248
10	Comparison of two clinical scales for causality assessment in hepatotoxicity. <i>Hepatology</i> , 2001, 33, 123-130.	3.6	240
11	Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. <i>Cell</i> , 2019, 177, 881-895.e17.	13.5	209
12	Glutathione <i>S</i> -transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2008, 48, 588-596.	3.6	181
13	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	0.6	174
14	Causality assessment methods in drug induced liver injury: Strengths and weaknesses. <i>Journal of Hepatology</i> , 2011, 55, 683-691.	1.8	164
15	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. <i>Hepatology</i> , 2006, 44, 850-856.	3.6	143
16	Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in Vigibase. <i>Drug Safety</i> , 2010, 33, 503-522.	1.4	142
17	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004, 39, 1603-1612.	3.6	134
18	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020, 94, 3381-3407.	1.9	125

#	ARTICLE	IF	CITATIONS
19	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	1.8	115
20	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 784-795.	0.7	108
21	Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. <i>World Journal of Hepatology</i> , 2014, 6, 160.	0.8	105
22	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010, 52, 303-312.	3.6	97
23	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	0.6	97
24	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 116-125.	1.9	95
25	Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2002, 40, 2-8.	0.3	92
26	Trovafloxacin-Induced Acute Hepatitis. <i>Clinical Infectious Diseases</i> , 2000, 30, 400-401.	2.9	91
27	Drug-induced liver injury: insights from genetic studies. <i>Pharmacogenomics</i> , 2009, 10, 1467-1487.	0.6	90
28	Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 820-827.	1.8	89
29	Mechanisms of drug-induced liver injury. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 286-292.	1.1	86
30	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. <i>Gastroenterology</i> , 2019, 157, 552-568.	0.6	85
31	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	2.4	83
32	HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. <i>PLoS ONE</i> , 2013, 8, e68111.	1.1	81
33	Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 507-516.	5.5	78
34	Hepatotoxicity Induced by Herbal and Dietary Supplements. <i>Seminars in Liver Disease</i> , 2014, 34, 172-193.	1.8	77
35	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. <i>Nature Communications</i> , 2017, 8, 2068.	5.8	77
36	Antidepressant-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 249-262.	1.0	75

#	ARTICLE	IF	CITATIONS
37	Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 435-440.	0.8	72
38	Analysis of IL-10, IL-4 and TNF- α polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008, 49, 107-114.	1.8	72
39	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97.	1.8	72
40	Causality assessment in drug-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 329-344.	1.0	70
41	Pharmacogenomics in Drug Induced Liver Injury. <i>Current Drug Metabolism</i> , 2009, 10, 956-970.	0.7	70
42	Mitofusin 2 as a Driver That Controls Energy Metabolism and Insulin Signaling. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1020-1031.	2.5	69
43	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2016, 17, 714.	1.8	69
44	Advanced preclinical models for evaluation of drug-induced liver injury “consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. <i>Journal of Hepatology</i> , 2021, 75, 935-959.	1.8	66
45	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. <i>Antioxidants</i> , 2021, 10, 390.	2.2	64
46	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. <i>International Journal of Molecular Sciences</i> , 2016, 17, 313.	1.8	63
47	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	2.3	58
48	Biomarkers in DILI: One More Step Forward. <i>Frontiers in Pharmacology</i> , 2016, 7, 267.	1.6	52
49	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.	2.3	52
50	A revised electronic version of RUCAM for the diagnosis of DILI. <i>Hepatology</i> , 2022, 76, 18-31.	3.6	52
51	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 817-828.	1.5	48
52	Rechallenge in drug-induced liver injury: the attractive hazard. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 709-714.	1.0	47
53	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015, 35, 2474-2482.	1.9	47
54	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 887-890.	0.8	45

#	ARTICLE	IF	CITATIONS
55	Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). <i>British Journal of Pharmacology</i> , 2007, 150, 808-815.	2.7	44
56	Drug-induced liver injury in older people. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 862-874.	3.7	42
57	Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. <i>Liver International</i> , 2016, 36, 302-310.	1.9	39
58	Acute liver failure after treatment with nefazodone. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2577-2579.	1.1	38
59	Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. <i>Liver International</i> , 2013, 33, 1378-1385.	1.9	38
60	Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. <i>Current Drug Safety</i> , 2010, 5, 212-222.	0.3	34
61	Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1080-1087.	0.9	34
62	Hepatic Damage by Natural Remedies. <i>Seminars in Liver Disease</i> , 2018, 38, 021-040.	1.8	33
63	Systematic review: ibuprofen-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 603-611.	1.9	32
64	Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. <i>Journal of Hepatology</i> , 2015, 62, 751-752.	1.8	31
65	Drug-induced liver injury: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 795-804.	1.0	31
66	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.	2.3	31
67	Drug use for non-hepatic associated conditions in patients with liver cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 71-76.	0.8	30
68	Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. <i>Drug Safety</i> , 2016, 39, 925-943.	1.4	30
69	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019, 7, 825-837.	1.6	29
70	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2021, 164, 105404.	3.1	29
71	Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. <i>Pharmacological Research</i> , 2022, 182, 106348.	3.1	29
72	Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1400-1404.	1.1	28

#	ARTICLE	IF	CITATIONS
73	A morphological method for ammonia detection in liver. PLoS ONE, 2017, 12, e0173914.	1.1	28
74	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Annals of Hepatology, 2014, 13, 231-239.	0.6	27
75	Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. Acta Pharmaceutica Sinica B, 2021, 11, 3685-3726.	5.7	27
76	Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review. Current Drug Safety, 2007, 2, 97-112.	0.3	26
77	Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clinical Therapeutics, 2009, 31, 1014-1019.	1.1	26
78	Hepatotoxicity induced by coxibs: how concerned should we be?. Expert Opinion on Drug Safety, 2016, 15, 1463-1475.	1.0	26
79	Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver International, 2017, 37, 132-140.	1.9	25
80	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Frontiers in Genetics, 2012, 3, 273.	1.1	23
81	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. Journal of Hepatology, 2021, 75, 333-341.	1.8	23
82	EASL Clinical Practice Guideline: Occupational liver diseases. Journal of Hepatology, 2019, 71, 1022-1037.	1.8	22
83	Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 153-169.	1.5	22
84	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. Pharmacogenetics and Genomics, 2016, 26, 414-422.	0.7	21
85	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). Clinical Liver Disease, 2019, 13, 51-57.	1.0	21
86	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. Clinical Gastroenterology and Hepatology, 2022, 20, e548-e563.	2.4	21
87	Norfloxacin-Induced Cholestatic Jaundice. American Journal of Gastroenterology, 1998, 93, 2309-2311.	0.2	20
88	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. Seminars in Liver Disease, 2019, 39, 381-394.	1.8	20
89	Chronic Hepatitis C, Ibuprofen, and Liver Damage. American Journal of Gastroenterology, 2002, 97, 1854-1855.	0.2	19
90	Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. Annals of Pharmacotherapy, 2004, 38, 1540-1541.	0.9	19

#	ARTICLE	IF	CITATIONS
91	Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. PLoS ONE, 2014, 9, e94675.	1.1	19
92	Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Review of Clinical Pharmacology, 2008, 1, 261-276.	1.3	18
93	Acetaminophen-Induced Liver Injury Alters the Acyl Ethanolamine-Based Anti-Inflammatory Signaling System in Liver. Frontiers in Pharmacology, 2017, 8, 705.	1.6	18
94	Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. Clinical Pharmacology and Therapeutics, 2018, 103, 843-853.	2.3	18
95	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. Clinical Gastroenterology and Hepatology, 2018, 16, 292-294.	2.4	18
96	Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. World Journal of Gastroenterology, 2006, 12, 5244-6.	1.4	18
97	N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. Frontiers in Pharmacology, 2022, 13, .	1.6	18
98	“Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge” Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 589-593.	1.5	17
99	The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. European Journal of Gastroenterology and Hepatology, 2005, 17, 59-63.	0.8	16
100	Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge. Digestive Diseases and Sciences, 2011, 56, 2501-2503.	1.1	16
101	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. Clinical Pharmacology and Therapeutics, 2021, 109, 1147-1158.	2.3	16
102	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1604-1612.	2.3	15
103	Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatology Communications, 2022, 6, 1895-1909.	2.0	15
104	Differential hepatoprotective role of the cannabinoid CB ₁ and CB ₂ receptors in paracetamol-induced liver injury. British Journal of Pharmacology, 2020, 177, 3309-3326.	2.7	13
105	Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. Phytotherapy Research, 2021, 35, 6-19.	2.8	13
106	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. Current Pharmaceutical Design, 2019, 25, 3855-3871.	0.9	13
107	Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. Frontiers in Genetics, 2012, 3, 253.	1.1	12
108	Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology. Frontiers in Pharmacology, 2012, 3, 2.	1.6	11

#	ARTICLE	IF	CITATIONS
109	Effect of cyclosporin a on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. <i>Thrombosis Research</i> , 1996, 81, 367-381.	0.8	10
110	The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. <i>Liver International</i> , 2018, 39, 401-410.	1.9	10
111	Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. <i>Frontiers in Genetics</i> , 2019, 10, 134.	1.1	10
112	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. <i>Liver International</i> , 2020, 41, 1523-1531.	1.9	10
113	Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <i>Annals of Hepatology</i> , 2014, 13, 231-9.	0.6	9
114	Pro-Euro-Dili Registry: A Collaborative Effort to Enhance the Understanding of Dili. <i>Journal of Hepatology</i> , 2016, 64, S293-S294.	1.8	8
115	Syndrome of inappropriate antidiuresis in doxylamine overdose. <i>BMJ Case Reports</i> , 2012, 2012, bcr-2012-007428-bcr-2012-007428.	0.2	7
116	Serious liver injury induced by Nimesulide: an international collaborative study. <i>Archives of Toxicology</i> , 2021, 95, 1475-1487.	1.9	7
117	Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. <i>Genes</i> , 2020, 11, 1275.	1.0	6
118	Characterizing Highly Cited Papers in Mass Cytometry through H-Classics. <i>Biology</i> , 2021, 10, 104.	1.3	6
119	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S439.	1.8	5
120	Use of Drugs Related to the Treatment of Diabetes Mellitus and Other Cardiovascular Risk Factors in the Spanish Population. The Di@bet.es Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 854-863.	0.4	5
121	Heterologous COVID-19 Vaccination in Spain: A Case Study of Individual Autonomy in the Real World. <i>Value in Health</i> , 2022, 25, 770-772.	0.1	5
122	PP022 Variations in drug-induced liver injury (DILI) between different prospective dili registries. <i>Clinical Therapeutics</i> , 2013, 35, e24.	1.1	4
123	518 THE SPANISH-LATIN AMERICAN DILI NETWORK: PRELIMINARY RESULTS FROM A COLLABORATIVE STRATEGIC INITIATIVE. <i>Journal of Hepatology</i> , 2013, 58, S212-S213.	1.8	4
124	The usefulness of TV medical dramas for teaching clinical pharmacology: A content analysis of House, M.D.. <i>Educacion Medica</i> , 2019, 20, 295-303.	0.3	4
125	Statins: Hepatic Disease and Hepatotoxicity Risk. <i>The Open Gastroenterology Journal</i> , 2008, 2, 18-23.	0.1	4
126	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. <i>Biomedicines</i> , 2022, 10, 55.	1.4	4

#	ARTICLE	IF	CITATIONS
127	Reflections on Running Training Workshops for Research Ethics Committee Members in Spain Between 2001 and 2008. <i>Croatian Medical Journal</i> , 2010, 51, 552-559.	0.2	3
128	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 280.	1.6	3
129	A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. <i>American Journal of Gastroenterology</i> , 2017, 112, 384-385.	0.2	3
130	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. <i>Current Hepatology Reports</i> , 2017, 16, 286-292.	0.4	3
131	Drug-induced liver and skin reactions: In need of a consensus definition. <i>Hepatology</i> , 2017, 65, 391-391.	3.6	3
132	DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. <i>Journal of Hepatology</i> , 2018, 68, S601.	1.8	3
133	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. <i>Archives of Toxicology</i> , 2021, 95, 1793-1803.	1.9	3
134	Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic β -adrenoceptors?. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009568-bcr2013009568.	0.2	3
135	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. <i>Journal of Clinical Medicine</i> , 2021, 10, 5317.	1.0	3
136	Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. <i>Antioxidants</i> , 2022, 11, 897.	2.2	3
137	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 477-496.	0.1	2
138	Corrigendum to "Analysis of IL-10, IL-4 and TNF- α polymorphisms in drug-induced liver injury (DILI) and its outcome" [<i>J Hepatol</i> 49 (2008) 107-114]. <i>Journal of Hepatology</i> , 2009, 50, 636.	1.8	1
139	486 IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN PATIENTS WITH PRE-EXISTING LIVER DISEASE: AN ANALYSIS OF THE CASES INCLUDED IN THE SPANISH DILI REGISTRY. <i>Journal of Hepatology</i> , 2011, 54, S199.	1.8	1
140	Factores de riesgo y mecanismos de toxicidad hepática. Daño hepático inducido por medicamentos y tóxicos (excluido el alcohol). <i>Medicine</i> , 2012, 11, 573-580.	0.0	1
141	Causality Assessment. , 2013, , 287-302.		1
142	P1097 : Distinguishing drug induced autoimmune hepatitis from idiopathic autoimmune hepatitis. <i>Journal of Hepatology</i> , 2015, 62, S761.	1.8	1
143	FRI-077-Influence of drug categorization according to labelling information in the phenotypic presentation of drug-induced liver injury (DILI): An analysis in the Spanish DILI registry. <i>Journal of Hepatology</i> , 2019, 70, e418.	1.8	1
144	P041... Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .		1

#	ARTICLE	IF	CITATIONS
145	Reply. Hepatology, 2022, 76, E28-E28.	3.6	1
146	Reply:. Hepatology, 2009, 49, 1777-1779.	3.6	0
147	Un caso de hepatopatía tóxica. Medicine, 2012, 11, 624.e1-624.e4.	0.0	0
148	PP025 "Improving hyaluronan's law definition to better predict the risk of developing acute liver failure in drug-induced liver injury (DILI). Clinical Therapeutics, 2013, 35, e25.	1.1	0
149	Reply. Gastroenterology, 2014, 147, 1442.	0.6	0
150	P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH "LATIN-AMERICAN DILI REGISTRY. Journal of Hepatology, 2014, 60, S169.	1.8	0
151	P309 PROGNOSTIC MODEL FOR PREDICTING DRUG-INDUCED ACUTE LIVER FAILURE. Journal of Hepatology, 2014, 60, S169.	1.8	0
152	Hepatotoxicity related to Herbs and Dietary Supplements (HDS): a cause for concern. Clinical Therapeutics, 2015, 37, e123.	1.1	0
153	Metabolic risk factors affect clinical Phenotype and outcome of Hepatotoxicity (DILI). Clinical Therapeutics, 2015, 37, e126-e127.	1.1	0
154	Clinical Networks And Consortia In Drug-Induced Liver Injury (Dili): An Opportunity For Advancing Safety Science. Clinical Therapeutics, 2015, 37, e166.	1.1	0
155	Reply. Gastroenterology, 2015, 148, 452-453.	0.6	0
156	P1098 : Influence of metabolic risk factors in hepatotoxicity (DILI) phenotype and outcome. Journal of Hepatology, 2015, 62, S761-S762.	1.8	0
157	Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide from the Spanish and Latin-American Dili Registries. Journal of Hepatology, 2016, 64, S239-S240.	1.8	0
158	Data Mining for Possible Drug-Host Interplay in Clinical Phenotypes of Drug-Induced Liver Injury. Gastroenterology, 2017, 152, S1080-S1081.	0.6	0
159	Jnk2 is indispensable in murine and human Ibuprofen-induced acute liver failure. Journal of Hepatology, 2017, 66, S400.	1.8	0
160	Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. , 2018, , 625-650.		0
161	Reply letter to "Editorial: bodybuilders beware". Alimentary Pharmacology and Therapeutics, 2019, 50, 473-473.	1.9	0
162	FRI-078-Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases. Journal of Hepatology, 2019, 70, e418-e419.	1.8	0

#	ARTICLE	IF	CITATIONS
163	Data mining techniques to identify potential clinical presentation modulators in drug-induced liver injury. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-9-13.	0.0	0
164	Reply. Hepatology, 2022, 76, E73-E73.	3.6	0